Pharmacodynamics of Free VEGF After Treatment with the Port Delivery Platform with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration. (PubMed, Ophthalmol Sci) - Sep 26, 2026 - P2, P3 | "These findings demonstrate that PDS 100 mg/mL Q24W suppresses AH free VEGF throughout the entire 24-week refill-exchange interval and to an extent similar to that at 4 weeks after intravitreal ranibizumab. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."
Journal • PK/PD data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
|
|
Katie F Maass; Mauricio Maia; Michael C Chang; Shamika Gune
|